Correlation of TLK1B in Elevation and Recurrence in Doxorubicin-Treated Breast Cancer Patients with High eIF4E Overexpression

Journal of the American College of Surgeons

Volumn 204, Issue 5, 2007, Pages 925-933

  Byrnes, Kerry W ^a   DeBenedetti, Arrigo ^b   Holm, Neal T ^a   Luke, Jay ^a   Nunez, Jade ^a   Chu, Quyen D ^a   Meschonat, Carol ^a   Abreo, Fleurette ^a   Johnson, Lester W ^c   Li, Benjamin D L ^a  

^a Louisiana State University Health Sciences Center   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c EA Conway Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; INITIATION FACTOR 4E; THREONINE; TOUSLED LIKE KINASE 1B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DOXORUBICIN; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT;

EID: 34247510546     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.02.027     Document Type: Article

References (26)

1. DeBenedetti A., and Harris A.L. EIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31 (1999) 59-72
2. Rhoads R.E., Joshi-Barve S., and Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects of mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol 46 (1993) 183-219
3. Sonenberg N., and Gingras A.C. The mRNA 5[prime] cap-binding protein eIF4E and control on cell growth. Curr Opin Cell Biol 10 (1998) 268-275
4. Gingras A.C., Raught B., Gygi S.P., et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15 (2001) 2852-2864
5. Koromilas A.E., Lazaris-Karatzas A., and Sonenberg N. mRNAs containing extensive secondary stucture in their 5[prime] non-coding region translate efficiently in cells overexpressing initiation factor 4E. EMBO J 11 (1992) 4153-4158
6. Rosenwald I.B., Lazaris-Karatzas A., Sonenberg N., et al. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13 (1993) 7358-7363
7. Kevil C., DeBenedetti A., Payne D.K., et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 65 (1996) 786
8. Kevil C., Carter P., Hu B., and DeBenedetti A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 11 (1995) 2339-2348
9. Li Y., DeFatta R., Anthony C., et al. A translationally regulated tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 20 (2001) 726-738
10. Kerekatte V., Smiley K., Hu B., et al. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64 (1995) 27
11. Vazquez S.H., Byrnes K., Chu Q., et al. Eukaryotic factor 4E (eIF4E) expression in malignant versus inflammatory colon tissue. Ann Surg Oncol 12 (2005) S90-S91
12. Nathan C.O., Liu L., Li B.D.L., et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 15 (1997) 579-584
13. Chu Q.D., Turnage R., McClusky D., et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) in soft tissue neoplasms. Proceedings of the AACR 45 (2004) 4285
14. Li B.D.L., McDonald J.C., Nassar R., et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227 (1998) 756-763
15. Li B.D.L., Gruner J.S., Abreo F., et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235 (2002) 732-739
16. McClusky D., Chu Q., Yu H., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242 (2005) 584-592
17. Byrnes K., White S., Chu Q., et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243 (2006) 684-692
18. Nathan C.O., Franklin S., Abreo F., et al. Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer. J Clin Oncol 17 (1999) 2909-2914
19. Sunavala-Dossabhoy G., Fowler M., and De Benedetti A. Translation of the radioresistance kinase TLK1B is induced by gamma-irradiation through the activation of mTOR and phosphorylation of 4E-BP1. BMC Mol Biol 5 (2004) 1
20. Sunavala-Dossabhoy G., Balakrishnan S., Sen S., et al. The radioresistance kinase TLK1B protects cells by promoting repair of double strand breaks. BMC Mol Biol 6 (2005) 19
21. Norton K., McClusky D., De Benedetti A., et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 116 (2004) 98-103
22. Wolfort R., De Benedetti A., Nuthalapaty S., et al. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 140 (2006) 161-169
23. Liang K., Lu Y., Li X., et al. Differential roles of phosphoinositide-dependent protein kinase-1 and AKT1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gencitabine. Mol Pharmacol 70 (2006) 1045-1052
24. Salvatore C., Camarda G., Maggi C.A., et al. NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol 27 (2005) 799-806
25. Lee E., Nichols P., Spicer D., et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66 (2006) 7849-7853
26. Knuefermann C., Lu Y., Liu B., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22 (2003) 3205-3212